Nine Java Enhancement Proposals make the final cut as OpenJDK shifts from feature development to bug fixing ahead of a September release.

The Java Community Process formally launches development of Java SE 28, with Project Valhalla once again positioned as the release's most closely watched feature.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

The largest workforce reduction in Oracle's 49-year history crossed a legal threshold today, June 1, as the first cohort of U.S. employees reached their official last working day under the federal ...

Some Canadians will be able to buy brand-name GLP-1 drug Ozempic at a reduced price, Danish drugmaker Novo Nordisk said in a statement Tuesday. The move comes as two generic versions of Ozempic and ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...